Updated:
Greenbrook TMS Inc.
Greenbrook TMS Inc. provides transcranial magnetic stimulation (TMS) therapy and esketamine nasal spray (SPRAVATO) at centers across the United States.
Greenbrook TMS Inc.
Greenbrook TMS Inc. provides transcranial magnetic stimulation (TMS) therapy and esketamine nasal spray (SPRAVATO) at centers across the United States. The firm, headquartered in Toronto, Canada, focuses on treatment-resistant depression and major depressive disorder. The company deploys capital into clinic expansion and treatment infrastructure. Its asset-class mix includes real estate (clinic leases), medical equipment (NeuroStar TMS devices), and operational cash flow from insurance reimbursements. Greenbrook handles patient insurance claims directly, covering Medicare, Medicaid, and major private plans. Geographic footprint spans multiple US states with convenient locations near patients' homes or workplaces. Greenbrook has delivered over 1.61 million treatments to date, per its website. The care team includes psychiatrists and operational staff at each clinic. Chief Medical Officer Dr. Geoffrey Grammer oversees clinical protocols. The firm supports nonprofit partners such as the American Foundation for Suicide Prevention and This Is My Brave. Greenbrook differentiates itself by offering two FDA-cleared or FDA-approved non-medication treatments under one roof, with a unified insurance-billing model that aims to remove access barriers for patients.
General information
Firm type
Healthcare Services Provider
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
Canada
City
Toronto
Corporate office
Toronto, Canada
Principals
Dr. Geoffrey Grammer
Chief Medical Officer
Sector focus
Frequently asked questions
What treatments does Greenbrook TMS offer?
Greenbrook offers NeuroStar Transcranial Magnetic Stimulation (TMS) therapy, an FDA-cleared non-invasive treatment for depression, and SPRAVATO esketamine nasal spray, an FDA-approved treatment for treatment-resistant depression. Both are administered at its US mental wellness centers.
Who oversees clinical care at Greenbrook?
Dr. Geoffrey Grammer serves as Greenbrook's Chief Medical Officer. The company employs a care team of psychiatrists and staff at each clinic location to manage patient treatment protocols.
Does Greenbrook accept insurance for its treatments?
Yes, Greenbrook states that its treatments are covered by most major insurance plans, including Medicare and Medicaid at various locations. The company handles all insurance paperwork, including filing claims and appeals.
What is the difference between NeuroStar TMS and SPRAVATO?
NeuroStar TMS uses electromagnetic stimulation to target brain regions associated with mood regulation and is non-invasive with no drug-related side effects. SPRAVATO is a ketamine-based nasal spray self-administered at Greenbrook centers for depression in adults who have not responded adequately to oral antidepressants.
How many treatments has Greenbrook delivered to date?
According to the firm's website, Greenbrook has provided more than 1.61 million treatments to patients struggling with depression.
Is Greenbrook tied to any philanthropic organizations?
Greenbrook supports the American Foundation for Suicide Prevention, This Is My Brave, and Pride celebrations, per its website. These partnerships are separate from its clinical operations and aim to reduce mental health stigma.
What regions does Greenbrook serve?
Greenbrook has multiple clinic locations across the United States, with its corporate headquarters in Toronto, Canada. The company aims to place centers close to patients' homes, work, or schools for convenient access.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: